Header Logo

Connection

Jacob Rotmensch to MAP Kinase Kinase 1

Back to Details
This is a "connection" page, showing publications Jacob Rotmensch has written about MAP Kinase Kinase 1.
Jacob Rotmensch
Connection Strength
0.120
MAP Kinase Kinase 1
  1. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):30-5.
    View in: PubMed
    Score: 0.120
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.